Smoked CBD cigarettes as add-on for psychosis showed hints of medication-sparing effects
In a small pilot trial of CBD cigarettes as adjunctive therapy for acute psychosis, both groups improved on symptom scores, but the placebo group required increased antipsychotic medication while the CBD group did not.
Quick Facts
What This Study Found
No significant group differences on primary outcomes (PANSS, BDI) after 4 weeks. Both groups showed decreases in psychotic symptoms and depression scores. However, the placebo group required increases in antipsychotic medication equivalent during the trial while the CBD group did not, suggesting a potential antipsychotic medication-sparing effect of smoked CBD.
Key Numbers
Small sample (exact N not specified in abstract). 4-week treatment. Both groups: decreased PANSS and BDI. Placebo group: increased antipsychotic medication equivalent. CBD group: no medication increase needed.
How They Did This
Randomized, open-label pilot trial. Patients with acute psychosis received either CBD-rich cannabis cigarettes (low THC) or placebo cigarettes as adjunctive therapy to treatment as usual. Primary outcomes: PANSS (psychotic symptoms) and BDI (depression) at 4 weeks.
Why This Research Matters
This is the first study to test smoked CBD (rather than oral) for psychosis. While inconclusive due to small sample size, the medication-sparing signal is clinically interesting because reducing antipsychotic doses could lower side effect burden for patients.
The Bigger Picture
Previous oral CBD studies (e.g., McGuire et al., 2018) showed antipsychotic effects. This pilot extends the question to inhaled CBD, which has faster onset and different pharmacokinetics. The medication-sparing finding, if confirmed, could meaningfully improve patient quality of life.
What This Study Doesn't Tell Us
Very small sample. Open-label (not blinded). No fixed dosing regimen. Smoked delivery introduces additional variables. Cannot draw conclusions from non-significant primary outcomes with inadequate power.
Questions This Raises
- ?Would a larger blinded trial confirm the medication-sparing effect?
- ?Is smoked CBD a practical long-term delivery method for psychosis patients?
- ?Could the act of smoking itself have placebo effects?
Trust & Context
- Key Stat:
- CBD group did not need antipsychotic dose increases while placebo group did
- Evidence Grade:
- Very small open-label pilot with non-significant primary outcomes. The medication-sparing observation is hypothesis-generating only.
- Study Age:
- 2021 pilot trial from Switzerland.
- Original Title:
- Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study.
- Published In:
- Frontiers in psychiatry, 12, 736822 (2021)
- Authors:
- Köck, Patrick(2), Lang, Elisabeth(2), Trulley, Valerie-Noelle, Dechent, Frieder, Mercer-Chalmers-Bender, Katja, Frei, Priska, Huber, Christian, Borgwardt, Stefan
- Database ID:
- RTHC-03249
Evidence Hierarchy
A small preliminary study to test whether a larger study is feasible.
What do these levels mean? →Frequently Asked Questions
Did CBD cigarettes reduce psychotic symptoms?
Both the CBD and placebo groups showed symptom improvement, with no significant difference between them. The study was too small to detect moderate-sized effects.
What was the medication-sparing effect?
Patients in the placebo group needed increases in their antipsychotic medication during the trial, while those receiving CBD cigarettes did not, suggesting CBD may reduce the need for higher antipsychotic doses.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-03249APA
Köck, Patrick; Lang, Elisabeth; Trulley, Valerie-Noelle; Dechent, Frieder; Mercer-Chalmers-Bender, Katja; Frei, Priska; Huber, Christian; Borgwardt, Stefan. (2021). Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study.. Frontiers in psychiatry, 12, 736822. https://doi.org/10.3389/fpsyt.2021.736822
MLA
Köck, Patrick, et al. "Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders - A Randomized, Open-Label Pilot-Study.." Frontiers in psychiatry, 2021. https://doi.org/10.3389/fpsyt.2021.736822
RethinkTHC
RethinkTHC Research Database. "Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic..." RTHC-03249. Retrieved from https://rethinkthc.com/research/kock-2021-cannabidiol-cigarettes-as-adjunctive
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.